Clinical Trial Update: Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the optimal Tamoxifen dose for breast cancer risk reduction in premenopausal women (RENAISSANCE). The study is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Atypical Ductal Hyperplasia
• Breast Atypical Lobular Hyperplasia
• Breast Cancer
• Ductal Carcinoma in Situ
• Estrogen Receptor-positive Breast Cancer
• Lobular Carcinoma in Situ

Drugs mentioned

• Tamoxifen (tamoxifen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia | Phase 2 | Status: RECRUITING